Upexi (UPXI) Competitors

Upexi logo
$0.46 -0.09 (-15.70%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.49 +0.03 (+5.80%)
As of 11/20/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UPXI vs. TONX, HUCK, CNTN, HSDT, and NAKA

Should you buy Upexi stock or one of its competitors? Upexi's main competitors and comparable companies include Verb Technology (TONX), Domo (HUCK), Hillstream Biopharma (CNTN), Solana (HSDT), and KindlyMD (NAKA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "multi-sector holdings" industry.

How does Upexi compare to Verb Technology?

Verb Technology (NASDAQ:TONX) and Upexi (NASDAQ:UPXI) are both small-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Verb Technology has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Upexi has a beta of -0.28, meaning that its stock price is 128% less volatile than the broader market.

In the previous week, Verb Technology's average media sentiment score of 0.00 equaled Upexi'saverage media sentiment score.

Company Overall Sentiment
Verb Technology Neutral
Upexi Neutral

Upexi has a consensus target price of $5.00, suggesting a potential upside of 981.78%. Given Upexi's stronger consensus rating and higher probable upside, analysts plainly believe Upexi is more favorable than Verb Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verb Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Upexi
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Verb Technology has higher earnings, but lower revenue than Upexi. Verb Technology is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verb Technology$12.78M10.74-$148.48M-$0.44N/A
Upexi$25M1.64-$246.07M-$4.14N/A

Verb Technology has a net margin of -603.43% compared to Upexi's net margin of -1,162.51%. Verb Technology's return on equity of -71.68% beat Upexi's return on equity.

Company Net Margins Return on Equity Return on Assets
Verb Technology-603.43% -71.68% -70.66%
Upexi -1,162.51%-157.49%-26.59%

7.2% of Verb Technology shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 21.4% of Verb Technology shares are owned by company insiders. Comparatively, 8.7% of Upexi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Verb Technology beats Upexi on 8 of the 13 factors compared between the two stocks.

How does Upexi compare to Domo?

Domo (NASDAQ:HUCK) and Upexi (NASDAQ:UPXI) are both small-cap finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

76.6% of Domo shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 13.3% of Domo shares are held by company insiders. Comparatively, 8.7% of Upexi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Domo has higher revenue and earnings than Upexi. Domo is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Domo$318.86M0.43-$59.34M-$0.98N/A
Upexi$25M1.64-$246.07M-$4.14N/A

In the previous week, Domo's average media sentiment score of 0.00 equaled Upexi'saverage media sentiment score.

Company Overall Sentiment
Domo Neutral
Upexi Neutral

Domo has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Upexi has a beta of -0.28, meaning that its share price is 128% less volatile than the broader market.

Domo has a net margin of -13.37% compared to Upexi's net margin of -1,162.51%. Domo's return on equity of 0.00% beat Upexi's return on equity.

Company Net Margins Return on Equity Return on Assets
Domo-13.37% N/A -25.13%
Upexi -1,162.51%-157.49%-26.59%

Domo currently has a consensus price target of $3.95, indicating a potential upside of 29.65%. Upexi has a consensus price target of $5.00, indicating a potential upside of 981.78%. Given Upexi's stronger consensus rating and higher possible upside, analysts plainly believe Upexi is more favorable than Domo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Domo
4 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
Upexi
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Domo beats Upexi on 9 of the 13 factors compared between the two stocks.

How does Upexi compare to Hillstream Biopharma?

Upexi (NASDAQ:UPXI) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

5.7% of Upexi shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 8.7% of Upexi shares are owned by company insiders. Comparatively, 3.3% of Hillstream Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Hillstream Biopharma had 3 more articles in the media than Upexi. MarketBeat recorded 3 mentions for Hillstream Biopharma and 0 mentions for Upexi. Hillstream Biopharma's average media sentiment score of 0.19 beat Upexi's score of 0.00 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Upexi Neutral
Hillstream Biopharma Neutral

Upexi presently has a consensus target price of $5.00, indicating a potential upside of 981.78%. Given Upexi's stronger consensus rating and higher possible upside, research analysts plainly believe Upexi is more favorable than Hillstream Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Upexi
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Hillstream Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Upexi has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Hillstream Biopharma has lower revenue, but higher earnings than Upexi. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Upexi$25M1.64-$246.07M-$4.14N/A
Hillstream BiopharmaN/AN/A-$35.92M-$0.50N/A

Hillstream Biopharma has a net margin of 0.00% compared to Upexi's net margin of -1,162.51%. Hillstream Biopharma's return on equity of -23.39% beat Upexi's return on equity.

Company Net Margins Return on Equity Return on Assets
Upexi-1,162.51% -157.49% -26.59%
Hillstream Biopharma N/A -23.39%-18.54%

Summary

Hillstream Biopharma beats Upexi on 8 of the 14 factors compared between the two stocks.

How does Upexi compare to Solana?

Upexi (NASDAQ:UPXI) and Solana (NASDAQ:HSDT) are both small-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

5.7% of Upexi shares are owned by institutional investors. Comparatively, 18.6% of Solana shares are owned by institutional investors. 8.7% of Upexi shares are owned by company insiders. Comparatively, 14.4% of Solana shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Upexi presently has a consensus price target of $5.00, indicating a potential upside of 981.78%. Solana has a consensus price target of $3.50, indicating a potential upside of 134.11%. Given Upexi's higher possible upside, equities analysts plainly believe Upexi is more favorable than Solana.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Upexi
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Solana
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Solana has lower revenue, but higher earnings than Upexi. Upexi is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Upexi$25M1.64-$246.07M-$4.14N/A
Solana$6.02M15.62-$40.89M$3.740.40

In the previous week, Solana had 2 more articles in the media than Upexi. MarketBeat recorded 2 mentions for Solana and 0 mentions for Upexi. Solana's average media sentiment score of 0.68 beat Upexi's score of 0.00 indicating that Solana is being referred to more favorably in the news media.

Company Overall Sentiment
Upexi Neutral
Solana Positive

Solana has a net margin of 2,040.43% compared to Upexi's net margin of -1,162.51%. Solana's return on equity of 128.12% beat Upexi's return on equity.

Company Net Margins Return on Equity Return on Assets
Upexi-1,162.51% -157.49% -26.59%
Solana 2,040.43%128.12%122.51%

Upexi has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, Solana has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Summary

Solana beats Upexi on 14 of the 16 factors compared between the two stocks.

How does Upexi compare to KindlyMD?

KindlyMD (NASDAQ:NAKA) and Upexi (NASDAQ:UPXI) are both small-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

KindlyMD has higher earnings, but lower revenue than Upexi. KindlyMD is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KindlyMD$1.82M34.68-$52.23M-$14.98N/A
Upexi$25M1.64-$246.07M-$4.14N/A

In the previous week, KindlyMD had 3 more articles in the media than Upexi. MarketBeat recorded 3 mentions for KindlyMD and 0 mentions for Upexi. Upexi's average media sentiment score of 0.00 beat KindlyMD's score of -0.38 indicating that Upexi is being referred to more favorably in the news media.

Company Overall Sentiment
KindlyMD Neutral
Upexi Neutral

KindlyMD currently has a consensus target price of $19.00, indicating a potential upside of 452.33%. Upexi has a consensus target price of $5.00, indicating a potential upside of 981.78%. Given Upexi's higher probable upside, analysts clearly believe Upexi is more favorable than KindlyMD.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KindlyMD
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Upexi
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

KindlyMD has a beta of 16.03, indicating that its stock price is 1,503% more volatile than the broader market. Comparatively, Upexi has a beta of -0.28, indicating that its stock price is 128% less volatile than the broader market.

5.7% of Upexi shares are owned by institutional investors. 24.1% of KindlyMD shares are owned by insiders. Comparatively, 8.7% of Upexi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

KindlyMD has a net margin of -1,067.93% compared to Upexi's net margin of -1,162.51%. KindlyMD's return on equity of -73.53% beat Upexi's return on equity.

Company Net Margins Return on Equity Return on Assets
KindlyMD-1,067.93% -73.53% -46.28%
Upexi -1,162.51%-157.49%-26.59%

Summary

KindlyMD beats Upexi on 9 of the 15 factors compared between the two stocks.

Get Upexi News Delivered to You Automatically

Sign up to receive the latest news and ratings for UPXI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UPXI vs. The Competition

MetricUpexiFinancial Services IndustryFinance SectorNASDAQ Exchange
Market Cap$53.93M$31.14B$12.76B$11.72B
Dividend YieldN/A7.46%4.97%4.72%
P/E Ratio-0.1121.7518.8928.09
Price / Sales1.645.995.005.42
Price / CashN/A20.5020.1621.90
Price / Book0.842.791.703.50
Net Income-$246.07M$1.13B$1.32B$394.12M
1 Month Performance-46.89%-11.25%-4.31%-12.15%
1 Year Performance-81.66%-11.96%2.06%-11.41%

Upexi Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UPXI
Upexi
1.3907 of 5 stars
$0.46
-15.7%
$5.00
+981.8%
-81.3%$53.93M$25MN/A10
TONX
Verb Technology
0.1912 of 5 stars
$3.22
+9.2%
N/AN/A$177.33M$12.78MN/A27
HUCK
Domo
1.0531 of 5 stars
$3.43
+16.3%
$3.95
+15.3%
-72.2%$154.86M$318.86MN/A920
CNTN
Hillstream Biopharma
0.1439 of 5 stars
$1.86
-3.6%
N/AN/A$148.21MN/AN/A12
HSDT
Solana
2.6899 of 5 stars
$1.83
-4.9%
$4.00
+119.2%
-54.0%$110.85M$6.02MN/A21

Related Companies and Tools


This page (NASDAQ:UPXI) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners